Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-18T06:31:06.975Z Has data issue: false hasContentIssue false
  • English
  • Français

The feasibility of harmonizing health technology assessments across jurisdictions: A case study of drug eluting stents

Published online by Cambridge University Press:  22 October 2009

Paul Trueman ,
Manjusha Hurry ,
Matthew Bending  and
John Hutton
Paul Trueman
Affiliation:
University of York
Manjusha Hurry
Affiliation:
University of York
Matthew Bending
Affiliation:
University of York
John Hutton
Affiliation:
University of York
Get access Rights & Permissions [Opens in a new window]

Abstract

Objectives: There is considerable interest in the potential for harmonizing health technology assessments (HTA) across jurisdictions. This study aims to consider four HTAs of drug eluting stents to determine the degree to which the methods adopted, evidence considered, and resulting recommendations diverge.

Methods: Four HTAs of drug eluting stents were selected for inclusion and evaluated using a framework developed to systematically capture information on the process adopted, the evidence considered and the recommendations of each HTA.

Results and Conclusions: The findings suggest that, although there is a common core data set considered by most of the agencies, differences in the approach to HTA, heterogeneity of studies, and the limited relevance of research findings to local practice meant that the core data set had only limited influence on the resulting recommendations. Of the HTA agencies considered in the analysis, many sought to generate additional primary research from local settings to help inform the development of recommendations that were relevant to local practice. This raises questions about the extent to which HTA methods can be harmonized across jurisdictions.

Keywords

Health technology assessmentHarmonizationDrug eluting stents
Type
General Essays
Information
International Journal of Technology Assessment in Health Care , Volume 25 , Issue 4 , October 2009 , pp. 455 - 462
Copyright
Copyright © Cambridge University Press 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Banta, D. The development of health technology assessment. Health Policy. 2003;63:121–132.CrossRefGoogle ScholarPubMed
2. Bowen, J, Hopkins, R, He, Y, et al. Systematic review and cost effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario. Final Report. PATH Research Institute; May 2007.Google Scholar
3. Busse, R, Orvain, J, Velasco, M, et al. Best practice in undertaking and reporting Health Technology Assessments. Int J Technol Assess Health Care. 2002;18:361–422.CrossRefGoogle Scholar
4. Centre for Reviews & Dissemination. Systematic reviews: CRD's guidance for undertaking reviews in healthcare. University of York, United Kingdom: Centre for Reviews & Dissemination; January 2009.Google Scholar
5. Core HTA. Drug eluting stents. European Network for Health Technology Assessment, work package 4, draft report, July 2007. http://www.eunethta.net/upload/WP4/EUnetHTA_WP4_CoreHTAonDES_FirstPublicDraftRevised-2007-07-11.pdf (accessed on April 22, 2009).Google Scholar
6. Cranovsky, R, Matillion, Y, Banta, HD. EUR-ASSESS project subgroup on coverage. Int. J Technol Assess Health Care. 1997;13:287–332.CrossRefGoogle ScholarPubMed
7. Culyer, AJ, Lomas, J. Deliberative processes and evidence-informed decision-making in health care: do they work and how might we know? Evid Policy. 2006;2:357–371.CrossRefGoogle Scholar
8. Hill, R, Boland, A, Dickson, R, et al. Drug eluting stents: A systematic review and economic evaluation. Health Technol Assess. 2007;11: iii, xi-221.CrossRefGoogle ScholarPubMed
9. HTA Core Model for Medical and Surgical Interventions. European Network for Health Technology Assessment, work package 4, draft report, July 2007. http://www.eunethta.net/upload/WP4/EUnetHTA_WP4_CoreModelforInterventions_FirstPublicDraftRevised-2007-07-11.pdf (accessed on April 22, 2009).Google Scholar
10. EUnetHTA: European Network for Health Technology Assessment. http://www.eunethta.net/Home/ (accessed April 21, 2009).Google Scholar
11. Hutton, J, Trueman, P, Facey, K. Harmonisation of evidence requirements for health technology assessment in reimbursement decision making. Int J Technol Assess Health Care. 2008;24:511–517.CrossRefGoogle Scholar
12. Jonsson, E, Banta, HD, Henshall, C, Sampietro-Colom, L. Summary report of the ECHTA/ECAHI project. European Collaboration for Health Technology Assessment/Assessment of Health Interventions. Int J Technol Assess Health Care. 2002;18:218–237.CrossRefGoogle ScholarPubMed
13. Kvas, E. Drug eluting stents in comparison to uncoated stents in the treatment of cardiopathy. Rapid Assessment. LBI-HTA 01, 2006.Google Scholar
14. Ong, AT, McFadden, EP, Regar, E, et al. Late angiographic stent thrombosis (LAST) events with drug eluting stents. J Am Coll Cardiol. 2005;45:2088–2092.CrossRefGoogle ScholarPubMed
15. Vinck, I, Neyt, M, Thiry, N, et al. Drug eluting stents in Belgium. Health technology assessment. Belgian Healthcare Knowledge Centre (KCE); 2007.Google Scholar
16. Weinstein, MC, O'Brien, B, Hornberger, J, et al. Principles of good practice for decision analytic modelling in health care evaluation: Report of the ISPOR task force on good research practices – modelling studies. Value Health. 2003;6:9–17.CrossRefGoogle Scholar